A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
Breast Neoplasms
Interventions
DRUG

Eribulin Mesylate

Eribulin mesylate IV infusion.

Trial Locations (18)

110060

Sir Ganga Ram Hospital, New Delhi

141002

Deep Hospital, Ludhiana

208002

J.K.Cancer Institute, Kanpur

226003

King George's Medical University,(Erstwhile Chhatrapati Shahuji Maharaj Medical University), Lucknow

226005

Ajanta Research Centre, Ajanta Hospital & IVF Centre, Lucknow

302001

Sawai Man Singh Hospital, Jaipur

380009

HEMATO-ONCOLOGY CLINIC Vedanta Institute of Medical Sciences, Ahmedabad

400012

Tata Memorial Hospital Department of Oncology, Mumbai

411033

Lokmanya Hospital, Pune

440026

HCG NCHRI Cancer Centre, Nagpur

500004

MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad

560027

HealthCare Global Enterprises Ltd, Bangalore

560072

Srinivasam Cancer Care Multispecialty Hospitals India Pvt Ltd, Bangalore

570001

KR Hospital Mysore Medical College, Mysore

700014

Nilratan Sircar Medical College and Hospital, Kolkata

700016

Netaji Subhash Chandra Bose Cancer Institute, Kolkata

700020

IPGME&R S.S.K.M Hospital, Kolkata

751019

All India Institute of Medical Sciences, Bhubaneswar

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT03583944 - A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter